Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy for lowering lipoprotein (a) levels

B Angelin1

  • 1Metabolism Unit, Huddinge University Hospital, Sweden.

Current Opinion in Lipidology
|December 31, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nutrition and stem cell integrity in aging.

Journal of internal medicine·2022
Same author

Founder effects facilitate the use of a genotyping-based approach to molecular diagnosis in Swedish patients with familial hypercholesterolaemia.

Journal of internal medicine·2021
Same author

Regulation of bile acid metabolism in biliary atresia: reduction of FGF19 by Kasai portoenterostomy and possible relation to early outcome.

Journal of internal medicine·2020
Same author

Asynchronous rhythms of circulating conjugated and unconjugated bile acids in the modulation of human metabolism.

Journal of internal medicine·2018
Same author

Unique case of cerebrotendinous xanthomatosis revisited: All the mutations responsible for this disease are present in the CYP27A1 gene.

Journal of internal medicine·2017
Same author

Can LDL cholesterol be too low? Possible risks of extremely low levels.

Journal of internal medicine·2017

High lipoprotein (a) levels increase cardiovascular disease risk. While genetic factors are understood, effective treatments to lower lipoprotein (a) are limited, necessitating consideration in aggressive lipid-lowering strategies.

Area of Science:

  • Cardiovascular Science
  • Lipid Metabolism
  • Genetics

Background:

  • Elevated lipoprotein (a) is a significant risk factor for atherosclerosis and cardiovascular disease.
  • The genetic regulation of lipoprotein (a) is well-understood, but therapeutic strategies for lowering its levels remain limited.
  • Lipoprotein (a) is a complex of apolipoprotein (a) and low-density lipoprotein (LDL).

Purpose of the Study:

  • To review the current understanding of lipoprotein (a) and its clinical implications.
  • To discuss the limited progress in developing effective treatments to lower plasma lipoprotein (a) levels.
  • To emphasize the importance of considering lipoprotein (a) levels in cardiovascular risk assessment and treatment decisions.

Main Methods:

  • Literature review of genetic regulation and therapeutic interventions for lipoprotein (a).

Related Experiment Videos

  • Analysis of existing methods for lowering lipoprotein (a), including pharmacological and apheresis techniques.
  • Discussion of clinical guidelines and risk stratification involving lipoprotein (a).

    • Main Results:

    • Despite understanding genetic regulation, effective methods to significantly lower lipoprotein (a) are scarce.
    • Certain interventions like nicotinic acid, sex hormones, anabolic steroids, and LDL apheresis can lower lipoprotein (a) levels.
    • These interventions allow for the evaluation of clinical response to lipoprotein (a) reduction.

    Conclusions:

    • Lipoprotein (a) is a critical, genetically influenced risk factor for cardiovascular disease.
    • Current therapeutic options for reducing lipoprotein (a) are limited, highlighting an unmet clinical need.
    • Evaluating an individual's lipoprotein (a) level is crucial when considering aggressive lipid-lowering treatments.